Importantly, the skeletal abnormalities observed following treatment with continuous PTH (cPTH) were virtually identical to those in patients undergoing renal dialysis reported here and in smaller studies.(9,10) Although the mechanisms underlying primary and secondary HPT differ, the skeletal consequences are similar (ie, osteitis fibrosa, elevated bone turnover, and defective bone matrix mineralization). The gene discussed is PTH; the disease is osteitis fibrosa.